戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  swabs (n=392) from symptomatic females with vaginal discharge.
2 y, presenting with anomalous bleeding and/or vaginal discharge.
3 l vaginosis (BV) is the most common cause of vaginal discharge.
4 y associated with cervicitis, urethritis, or vaginal discharge.
5 thral discharge and 200 female patients with vaginal discharge.
6 nal discharge or a clear, non-purulent mucus vaginal discharge.
7 cles were regular, and there was no abnormal vaginal discharge.
8 ial vaginosis (BV), the most common cause of vaginal discharge.
9 8 [1.6-2.0]), dizziness (1.7 [1.6-1.8]), and vaginal discharge (1.8 [1.7-2.0]).
10       These women were more likely to report vaginal discharge (76% versus 59%; P = 0.02) and have an
11  group had a higher rate of increased or new vaginal discharge (86.7% vs 46.0%; between-group differe
12 l vaginosis (BV) is the most common cause of vaginal discharge among reproductive-age women.
13 acterial vaginosis (BV) is a common cause of vaginal discharge and associated with vaginal acquisitio
14 d side effect profile between interventions (vaginal discharge and bleeding) and women randomised to
15 ymptoms, the 2 most powerful were history of vaginal discharge and history of vaginal irritation, whi
16 inical syndrome presenting with a malodorous vaginal discharge and increased vaginal pH.
17 I testing in women seeking care for abnormal vaginal discharge and inflammation.
18 I testing in women seeking care for abnormal vaginal discharge and inflammation.
19 l vaginosis (BV) is the most common cause of vaginal discharge and is associated with important publi
20 rformance of the WISH algorithms and the WHO vaginal discharge and lower abdominal pain algorithms wi
21                      However, algorithms for vaginal discharge and lower abdominal pain perform poorl
22 vestigated all women complaining of abnormal vaginal discharge and seeking care at maternal and child
23 iscrepant samples clustered among women with vaginal discharge and/or BV.
24 ate models, vulvitis, genital ulcer disease, vaginal discharge, and Candida vaginitis were significan
25 ined as a non-fetid purulent or mucopurulent vaginal discharge; and control cows, (CTL, n = 115) defi
26 VVC, M. hominis was associated with abnormal vaginal discharge (aOR = 2.70, 95%CI:1.92-3.79), vaginal
27 s, yet its prevalence and characteristics in vaginal discharge are not well understood.
28 laboratory tests, particularly microscopy of vaginal discharge, are the most useful way of diagnosing
29                                              Vaginal discharge as well as posterior hymenal transecti
30 ed search terms of diagnosis with vaginitis, vaginal discharge, candidiasis, bacterial vaginosis, and
31 econdary symptoms were dyspareunia, abnormal vaginal discharge, chronic pelvic pain, avoiding sexual
32 with watery, red or brown colored, and fetid vaginal discharge; cows with purulent discharge (PUS, n
33 infection but were elevated in women who had vaginal discharge, detectable HIV-1 RNA in their genital
34 rticipants with ulcers were symptomatic with vaginal discharge; four had ulcers identified when exami
35 st report of P. aerogenes isolation from sow vaginal discharge in Thailand.
36 he most recent sexual partner; and (c) itchy vaginal discharge in the previous 30 d, possibly indicat
37 orted vaginal malodor and clinician-recorded vaginal discharge in women with BV, but not with symptom
38  pain (LR, 0.8; 95% CI, 0.7-0.9), history of vaginal discharge (LR, 0.3; 95% CI, 0.1-0.9), history of
39 l vaginosis leaves patients with undesirable vaginal discharge, malodor, and discomfort.
40 l irritation (LR, 0.2; 95% CI, 0.1-0.9), and vaginal discharge on examination (LR, 0.7; 95% CI, 0.5-0
41 CTL, n = 115) defined as cows with either no vaginal discharge or a clear, non-purulent mucus vaginal
42  symptoms (eg, dysuria and frequency without vaginal discharge or irritation) raise the probability o
43  combination of dysuria and frequency but no vaginal discharge or irritation).
44 articularly gynecological complaints such as vaginal discharge (OR, 3.2; 95% CI, 2.2-4.8) and dyspare
45  of a symptomatic partner, dysuria, abnormal vaginal discharge, or a new sex partner during the prece
46 y, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamo
47 s receiving tamoxifen had significantly more vaginal discharge (P < .0001).
48                              The presence of vaginal discharge (positive likelihood ratio, 2.7; 95% c
49  or more of four clinical features (purulent vaginal discharge, pyrexia, uterine tenderness, and leuk
50 is study aimed to detect P. aerogenes in sow vaginal discharge samples and investigate its antibiotic
51           Women presenting for evaluation of vaginal discharge, STI exposure, or preventative gynecol
52  discharge syndrome and female patients with vaginal discharge syndrome were recruited from five prim
53 s associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal
54  trends, and determinants of aetiologies for vaginal discharge, urethral discharge, and genital ulcer
55  present with additional symptoms, including vaginal discharge, vaginal pain/pressure, suprapubic pai
56                          Self-reported itchy vaginal discharge was associated with all categories of
57 sed susceptibility to HIV acquisition, while vaginal discharge was not.
58         Syndromic STI diagnosis dependent on vaginal discharge was poorly predictive of laboratory-di
59            The incidence of new or increased vaginal discharge was significantly higher in the pessar
60                                              Vaginal discharge was thus a poor predictor of laborator
61   In 2015, estimated primary aetiologies for vaginal discharge were candidiasis (69.4% [95% confidenc
62 etritis (reddish-brownish, watery, and fetid vaginal discharge) were paired with cows without metriti
63 ds of condom use and increased odds of itchy vaginal discharge, which is potentially indicative of se
64 e seen for any endocrine symptoms apart from vaginal discharge, which was more pronounced with tamoxi
65 reported significantly fewer cold sweats and vaginal discharge, yet more vaginal dryness, painful int